Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to -$96.2 million.

  • Agios Pharmaceuticals' Cash from Operations rose 2775.01% to -$96.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$373.0 million, marking a year-over-year increase of 432.59%. This contributed to the annual value of -$373.0 million for FY2025, which is 432.59% up from last year.
  • As of Q4 2025, Agios Pharmaceuticals' Cash from Operations stood at -$96.2 million, which was up 2775.01% from -$88.2 million recorded in Q3 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Cash from Operations peaked at -$61.6 million during Q3 2023, and registered a low of -$133.2 million during Q4 2024.
  • Its 5-year average for Cash from Operations is -$88.8 million, with a median of -$84.7 million in 2021.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Cash from Operations skyrocketed by 3671.54% in 2022, and later plummeted by 8370.9% in 2024.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Cash from Operations stood at -$84.1 million in 2021, then rose by 21.32% to -$66.2 million in 2022, then fell by 9.56% to -$72.5 million in 2023, then tumbled by 83.71% to -$133.2 million in 2024, then grew by 27.75% to -$96.2 million in 2025.
  • Its Cash from Operations was -$96.2 million in Q4 2025, compared to -$88.2 million in Q3 2025 and -$77.1 million in Q2 2025.